NEUROPACE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.53 USD | -0.92% |
|
-7.83% | -26.96% |
| May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
| May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to NeuroPace's Fir...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brainâs electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Companyâs RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
Calendar
2024-05-28
- Wells Fargo 2024 West Coast MedTech Tour
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.53
USD
Average target price
17.21
USD
Spread / Average Target
+128.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.96% | 217M | |
| +10.03% | 223B | |
| +13.59% | 195B | |
| +20.01% | 144B | |
| +30.83% | 111B | |
| +2.05% | 65.01B | |
| +15.38% | 53.02B | |
| +3.96% | 50.45B | |
| +8.37% | 44.15B | |
| +3.27% | 36.45B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Transcript : NeuroPace, Inc., Q1 2024 Earnings Call, May 08, 2024
